Milestone Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1111 Boul Dr.-Frederik-Philips Suite 420...Phone Number
(514) 336-0444Website
www.milestonepharma.comRevenue
<$5 MillionStock Symbol
MISTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
2
1
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and advancing innovative cardiovascular medicines. The company specializes in creating therapies for heart rhythm disorders, with a focus on addressing unmet patient needs through clinical research and development. Its programs aim to provide effective treatment options for cardiovascular conditions while improving patient outcomes. Milestone operates across North America, collaborating with healthcare professionals and research partners to advance its therapeutic solutions.Explore more
Milestone Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Milestone Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Milestone Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Milestone Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Milestone Pharmaceuticals
Product Launch: Get notified when Milestone Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Milestone Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Milestone Pharmaceuticals recently announced quarterly report
Check if Milestone Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Milestone Pharmaceuticals is spiking on competitors!
Recommended Actions
Find VP level buyers at Milestone Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Milestone Pharmaceuticals
Compare insights from companies similar to Milestone Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Milestone Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Milestone Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Milestone Pharmaceuticals.
Milestone Pharmaceuticals financials insights
Gather financial insights about Milestone Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$13M
2015
Series B
$17M
2017
Series C
$55M
2018
Series D
$80M
2019
Stock Offering
$94.9M
2020
Share Placement
$25M
2023
Other Financing Round
$125M
Milestone Pharmaceuticals Tech Stack
A closer look at the technologies used by Milestone Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
reported that improved CARDAMYST formulary coverage is expected to drive increases in both prescription volumes and average selling prices in Q3 and Q4 2026, as physicians gain confidence that prescriptions will be filled and patients can access the product at their local pharmacy with a reasonable out-of-pocket cost.
Sales, Pharmaceuticals
Earnings
reported selling, general, and administrative expense of $22.6 million for Q2 2026, compared with $8.9 million for Q2 2025, and $43.3 million for the six months ended June 30, 2026, compared with $24.4 million for the same period in 2025, with the increase driven by additional personnel costs, professional costs, and other operational expenses related to the CARDAMYST launch.
Earnings, Finance
Earnings
reported a broad prescriber mix for CARDAMYST across electrophysiologists, clinical and interventional cardiologists, and nurse practitioners, with electrophysiologists demonstrating strong promotional response and earlier-than-expected adoption of the product.
Product Marketing, Doctors / Physicians, Pharmaceuticals, Clinical Operations
Earnings
Sales, Pricing
Milestone Pharmaceuticals News & Media
Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes
Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and Work Research Shows that Patients with PSVT Experience a Substantial Burden Between Episodes, with Negative Impacts on Anxiety, Daily Activities, Sleep, and WorkMilestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT)Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal sprayMilestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026
MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30am ET.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Milestone Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and advancing innovative cardiovascular medicines. The company specializes in creating therapies for heart rhythm disorders, with a focus on addressing unmet patient needs through clinical research and development. Its programs aim to provide effective treatment options... Read More
